- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
OmniAb Inc.(OABI)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for OABI
11/13/2026: OABI (1-star) has a low Upturn Star Rating. Not recommended to BUY.
OmniAb Inc. is a biotechnology company that provides a proprietary discovery platform, enabling partners to develop therapeutic antibodies. Its business model relies on licensing fees, development milestones, and long-term royalties, which provides a capital-light growth path. The primary investment opportunity lies in the success of the diverse pipeline developed by its pharmaceutical partners. However, investors face risks related to the company's reliance on third-party clinical success, potential technological obsolescence, and inherent price volatility. OmniAb may suit growth-oriented investors interested in the biotechnology discovery ecosystem, provided they are prepared to monitor clinical milestone progress as a key driver of long-term value.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company offers long-term growth potential through royalties, but it is currently in a high-investment, developmental phase. |
| Momentum investor | Weak fit | Momentum is often erratic in biotech platform companies and depends heavily on specific clinical trial outcomes by partners. |
| Value investor | Weak fit | Valuation is complex due to the intangible nature of future royalty streams rather than current cash flow. |
| Dividend investor | Weak fit | The company does not pay dividends and retains all capital for growth and operations. |
| Low-risk investor | Weak fit | Biotech platform companies are subject to high volatility and significant binary risks related to clinical progress. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock price is highly sensitive to news from partner clinical programs. |
| Valuation risk | Medium / high | Valuation relies on long-dated expectations of milestone and royalty income. |
| Competition risk (Discovery platforms) | Medium / high | New technologies could render current transgenic platform advantages obsolete. |
| Business quality | Medium | The royalty model provides high operating leverage but lacks control over end-product success. |
| Dividend income | Low / none | Income-focused investors will find no yield here. |
| Execution risk | Medium | The company must continuously innovate its platform to remain the preferred choice for drug developers. |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 716.17M USD | Price to earnings Ratio - | 1Y Target Price 8.33 |
Price to earnings Ratio - | 1Y Target Price 8.33 | ||
Volume (30-day avg) 1.4M shares | Beta 1.36 | 52 Weeks Range 1.35 - 5.45 | Updated Date 11/14/2026 |
52 Weeks Range 1.35 - 5.45 | Updated Date 11/14/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.34 |
Sector & Industry Intelligence
Sector
Healthcare
Bullish- Sentiment
- Strong Bullish
- Momentum
- Momentum Steady
- BUY participation
- 62.6%
- Active BUY / eligible
- 72 / 115
- 30-Day BUY Count Change
- +35
- Market state
- Strong Bullish
The number of qualifying BUY stocks has remained relatively stable.
Industry
Biotechnology
- BUY participation
- 45.5%
- Active BUY / eligible
- 20 / 44
- 30-Day BUY Count Change
- +13
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior

Hockey-Stick Growth
The stock demonstrates a Hockey-Stick Growth price path pattern.

Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit -35.32% | Avg. Invested days 24 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | Stock Returns Performance |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals 
Financial Health Rating 
Growth Momentum Score 
Ownership 
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue) 
Economic Dimensions
Quantitative Style Profile 
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Platform Licensing | Upfront fees, annual access fees, and research fees from partners using OmniAb technology. | The company earns money by letting other drug companies use their tools to find new medicines. |
| Milestone & Royalties | Payments triggered when partner programs reach clinical stages and royalties on future commercial sales. | The company gets paid when its partners' drug programs succeed in tests and eventually reach the market. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Valuation
Trailing PE - | Forward PE - | Enterprise Value 670.10M | Price to Sales(TTM) 17.81 |
Enterprise Value 670.10M | Price to Sales(TTM) 17.81 | ||
Enterprise Value to Revenue 16.66 | Enterprise Value to EBITDA -10.62 | Shares Outstanding 145.86M | Shares Floating 118.70M |
Shares Outstanding 145.86M | Shares Floating 118.70M | ||
Percent Insiders 15.55 | Percent Institutions 55.75 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

